A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
| العنوان: | A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19 |
|---|---|
| المؤلفون: | Masoomeh Raoufi, Mehran Kouchek, Fahimeh Hadavand, Mohammad Sistanizad, Shayesteh Khalili, Amirhossein Karagah, Seyedpouzhia Shojaei, Mahmood Nabavi, Alireza Manafi-Rasi, Mir Mohammad Miri, Saemeh Asgari, Mehrdad Haghighi, Simin Dokht Shoaei, Sara Salarian, Omid Moradi, Shahram Araghi, Morteza Jaffaraghaei, Amir Behnam Kharazmi, Setayesh Sadeghi |
| المصدر: | Immunity, Inflammation and Disease, Vol 10, Iss 2, Pp 201-208 (2022) Immunity, Inflammation and Disease |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Immunology, coronavirus, law.invention, Pharmacotherapy, Randomized controlled trial, law, COVID‐19, Intensive care, Internal medicine, medicine, Humans, Immunology and Allergy, Aged, Mechanical ventilation, Anakinra, SARS-CoV-2, business.industry, COVID-19, Original Articles, Middle Aged, acute respiratory distress syndrome, RC581-607, Respiration, Artificial, mortality, Clinical trial, Interleukin 1 Receptor Antagonist Protein, Treatment Outcome, Sample size determination, inflammation, Female, Original Article, interleukin‐1 inhibitor, Immunologic diseases. Allergy, business, medicine.drug, anakinra |
| الوصف: | Introduction Hyperinflammatory state has a role in the pathogenesis of COVID‐19. Anakinra could reduce inflammation and help to combat the condition. In this study, we aimed to assess the safety and efficacy of anakinra (PerkinRA®) in severe COVID‐19. Method The study was an open‐label, randomized, controlled trial conducted in Imam Hossein Medical Center from May to July 2020. Patients with a confirmed diagnosis of COVID‐19 were included in this study. We administered anakinra 100 mg daily intravenously. All patients received COVID‐19 pharmacotherapy based on the represented national guideline. The need for invasive mechanical ventilation is considered the primary outcome. Results Thirty patients were included in this study, and 15 of them received Anakinra. Nineteen patients were male (63.3%), and 11 were female (36.7%). The mean age of patients was 55.77 ± 15.89 years. In the intervention group, the need for invasive mechanical ventilation was significantly reduced compared to the control group (20.0% vs. 66.7%, p = .010). Also, these patients had a significantly lower length of hospital stay (p = .043). No significant higher rate of infection was recorded. Conclusion Anakinra as an immunomodulatory agent has been associated with the reduced need for mechanical ventilation in patients admitted to intensive care units because of severe COVID‐19. The medication reduced the hospital length of stay. Furthermore, no increased risk of infection was observed. Further randomized placebo‐controlled trials with a larger sample size are needed to confirm these findings. Anakinra administration significantly reduces the need for mechanical ventilation. No increased risk of infection was observed because of anakinra use. Reduced hospitalization duration observed in patients who received anakinra. |
| اللغة: | English |
| تدمد: | 2050-4527 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c2697c53a9fdbaf75940cf40f11a1aTest https://doaj.org/article/0b7715e22add4755a6232ef7e5c73537Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....67c2697c53a9fdbaf75940cf40f11a1a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20504527 |
|---|